Metformin, GLP-1 Agonists, and Skin Longevity: Emerging Dermatologic Insights
Clinical Summary
Metformin, GLP-1 Agonists, and Skin Longevity: Emerging Dermatologic Insights
-
Metformin (oral/topical): Existing dermatologic data support benefits for hyperpigmentation, wound healing, longevity biomarkers, and fibrosing disorders such as CCCA (central centrifugal cicatricial alopecia); effects on hyperpigmentation have also been observed with topical formulations.
-
GLP-1 receptor agonists: Early clinical observations include skin laxity and recurrence of atrophic acne scarring during weight loss, suggesting possible activation of senescence-related pathways.
-
Long-term skin effects: Despite early changes, prolonged GLP-1 use may ultimately improve skin appearance and hyperpigmentation; however, evidence for skin longevity remains preliminary, with metformin currently supported by stronger dermatologic data.
Reviewed by Riya Gandhi, MA, Associate Editor of Immunology Group
Dr Natasha Mesinkovska explores how metformin and GLP-1 receptor agonists may influence skin aging, pigmentation, wound healing, and longevity pathways. Learn what current evidence suggests about these metabolic therapies in dermatology, including their evolving role in hyperpigmentation, scarring alopecia, skin laxity, and the future of skin longevity science.
Transcript
Hi, my name is Dr Natasha Mesinkovska and I work at the University of California, Irvine, Department of Dermatology.
One of my talks at SCALE this year is kind of committed to regulating sugars in our bodies and the meaning to skin and skin longevity. We know now that losing weight and regulating sugars is all the hot stuff with GLP-1s, but really what I'm going to focus on is metformin and GLP-1s because all of the data that we really have is from metformin.
Metformin has been shown to be beneficial for skin, primarily in oral forms when it comes to hyperpigmentation, wound healing, and some of the longevity biomarkers. Hyperpigmentation has actually been reproduced even with topical preparations. We also know that for certain types of fibrosing conditions, such as scarring alopecias like CCCA, this can also be a very powerful modality, both when taken orally and applied topically.
So what about the GLP-1s? It's very interesting that even on the very lowest of the doses, we see some of the skin laxity. We see people that are 40 or 50 now getting some of the scars back from acne that they were teenagers. So there is something that's happening that is maybe turning on some of these senescent markers. But long term, I think we have not tapped into the story because I feel that people who have been on these medications for several years -- I don't feel actually, what I see is that their skin starts looking younger. The hyperpigmentation may get worse initially or some of the acne may come; with time, they tend to become better. But we will see.
The science on the GLP-1s for skin longevity is still early. Until then, we still have metformin to rely on.
